The Lilly PatientOne program is committed to helping eligible patients access support programs for Lilly Oncology products they have been prescribed. It aims to address both financial and coverage issues for qualified uninsured, underinsured, and insured patients who have been prescribed a Lilly Oncology product. Lilly PatientOne strives to offer resources, ranging from benefits investigations to financial assistance and appeals information, that provide reliable and individualized treatment support for eligible patients.
*This offer is invalid for patients whose prescription claims are eligible to be reimbursed, in whole or in part, by any governmental program.
You are now leaving the www.LARTRUVO.com website.
LARTRUVO is indicated, in combination with doxorubicin, for the treatment of adult patients with soft tissue sarcoma (STS) with a histologic subtype for which an anthracycline-containing regimen is appropriate and which is not amenable to curative treatment with radiotherapy or surgery.
This indication is approved under accelerated approval. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial.
Please see full Prescribing Information for LARTRUVO.
OR HCP ISI 19OCT2016